ArticleFrontiers in oncology2025
The association of molecular classification with fertility-sparing treatment of atypical endometrial hyperplasia and endometrial cancer: a retrospective study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Review
- Oncological and reproductive outcomes following fertility-preserving treatment in mismatch repair-deficient endometrial cancer or atypical endometrial hyperplasia.BMC women's health · 2026Article
- Molecular classification of endometrial cancer in fertility-sparing-treatment: toward a personalized clinical approach.Frontiers in oncology · 2026Review
- Prognostic and predictive roles of microsatellite instability and mismatch repair deficiency in early-stage endometrial cancer: a structured narrative review.Obstetrics & gynecology science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate whether molecular classification was associated with treatment response and recurrence in women with atypical endometrial hyperplasia (AEH) or early-stage endometrial cancer (EC) treated with progestin. Methods: A retrospective analysis of 116 patients (71 AEH and 45 EC) who received fertility-sparing therapy between 2010 and 2022 was performed. Tumors were classified via immunohistochemistry and gene sequencing into four subgroups: polymerase-ϵ (POLE)-mutated (POLEmut), tumor protein 53 (p53) wild type [p53wt; no specific molecular profile (NSMP)], mismatch repair deficient (MMRd), and p53 abnormal (p53abn). The primary outcome was complete response (CR) to hormone therapy. The secondary outcomes included the recurrence rate after CR and conception success. The treatment response to progestin and recurrence rate were compared across the four subgroups. Results: Of 116 patients, 10 (8.62%) were classified as POLEmut, 81 (69.82%) p53wt, 9 (7.76%) p53abn, and 16 (13.76%) MMRd. At the 12-month evaluation, 87 patients (75.00%) achieved CR (median treatment duration, 5.95 months; range, 1.6-12.9). Partial response (PR), stable disease (SD), and progressive disease (PD) rates were 6.89% (n = 8), 1.72% (n = 2), and 16.38% (n = 19), respectively. Patients with the p53abn and MMRd subtypes had lower CR rates (33.33% and 37.50%) and higher progression rates (44.40% and 37.50%) compared to other subgroups ( Conclusion: Molecular classification may be associated with hormone treatment response in patients with AEH, EC patients with POLEmut and p53wt had better progestin response, and those with MMRd and p53abn had the poorest response and the highest recurrence rate. Recurrence was common after CR, but close review is necessary. For further investigation of the role of molecular classification in fertility-sparing treatment of AEH/EC, larger prospective studies are necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.